Last edition
News about "Glenmark Specialty S.A."
Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer
Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.
Glenmark Specialty S.A. | 04/07/2026 | By News Bureau
Glenmark Advances Phase 3 Trial of Trastuzumab Rezetecan in Ovarian Cancer
Glenmark has advanced the phase 3 clinical trial of trastuzumab rezetecan for platinum-resistant ovarian cancer, with India becoming the first licensed market to approve the study extension.
Glenmark Specialty SA | 02/07/2026 | By News Bureau
Glenmark Specialty SA Receives US FDA Approval for Fluticasone Propionate Inhalation Aerosol USP
Glenmark Pharmaceuticals’s subsidiary Glenmark Specialty SA has received approval from the US Food and Drug Administration (FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, along with 180-day Competitive Generic Therapy exclusivity. The product has been deemed bioequivalent and therapeutically equivalent to Flovent HFA.
Glenmark Specialty SA | 05/03/2026 | By Akanki | 140
Glenmark Secures China's Approval For RYALTRIS
Glenmark Pharmaceuticals has received regulatory approval in China for RYALTRIS. Combining olopatadine hydrochloride and mometasone furoate, it offers dual-action relief from nasal symptoms, further strengthening Glenmark’s position as a global leader in respiratory innovation.
Glenmark Specialty S.A. | 11/11/2025 | By Dineshwori | 520
Glenmark Secures USD 1.0 Billion Licensing Deal for Next-Gen Cancer Drug with Chinese Partner
Under the terms of the deal, Glenmark will make an upfront payment of USD 18 million and may pay up to USD 1.093 billion in regulatory and commercial milestone payments, in addition to royalties tied to future sales.
Glenmark Specialty S.A. | 25/09/2025 | By Darshana | 271
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy